Winning Points Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

Winning Points Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-584	Closed	-$15K	–	81
2021 Q4	$15K	Buy	+584	New	+$17.6K	0.01%	69
2019 Q4	–	Sell	-18	Closed	-$3K	–	76
2019 Q3	$3K	Sell	18 -1	-5%	-$451	﹤0.01%	70
2019 Q2	$15K	Sell	19 -4	-17%	-$3.65K	0.01%	69
2019 Q1	$24K	Sell	23 -11	-32%	-$10.7K	0.02%	69
2018 Q4	$28K	Hold	34	–	–	0.02%	68
2018 Q3	$25K	Sell	34 -4	-11%	-$10.9K	0.02%	73
2018 Q2	$146K	Hold	38	–	–	0.12%	68
2018 Q1	$141K	Hold	38	–	–	0.12%	71
2017 Q4	$183K	Sell	38 -2	-5%	-$12.4K	0.15%	70
2017 Q3	$254K	Sell	40 -1	-2%	-$6.19K	0.22%	62
2017 Q2	$289K	Buy	+41	New	+$381K	0.28%	58

Other funds holding TTNP

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Winning Points Advisors's TTNP Position: Q1 2022 in Review

Winning Points Advisors sold out of Titan Pharmaceuticals (TTNP) in Q1 2022, closing a stake of 584 shares — an estimated $15K sold.

Winning Points Advisors first reported a position in TTNP in Q2 2017 and held it in 11 quarters. The position peaked at $289K in Q2 2017. 18 funds tracked by Wall St. Rank hold TTNP as of Q1 2022.

Winning Points Advisors reported no remaining Titan Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Winning Points Advisors sold 584 Titan Pharmaceuticals shares in Q1 2022, an estimated $15K.
Winning Points Advisors first reported a position in Titan Pharmaceuticals in Q2 2017 and held it in 11 quarters.
Winning Points Advisors's Titan Pharmaceuticals position peaked at $289K in Q2 2017.
18 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2022.

Based on Winning Points Advisors's 13F filing for Q1 2022, filed 27 Apr 2022.